BioMarin Pharmaceutical Inc. (BMRN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
As of 03:48PM EDT. Market open.
| Previous Close | 82.10 |
| Open | 82.40 |
| Bid | 82.76 x 100 |
| Ask | 83.10 x 200 |
| Day's Range | 81.81 - 83.02 |
| 52 Week Range | 76.02 - 99.56 |
| Volume | |
| Avg. Volume | 1,546,978 |
| Market Cap | 15.741B |
| Beta (5Y Monthly) | 0.32 |
| PE Ratio (TTM) | 78.21 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand have been highlighted in this Industry Outlook article.
- GuruFocus.com
Insider Sale: EVP, Chief Commercial Officer Jeffrey Ajer Sells 5,000 Shares of Biomarin ...
On May 2, 2024, Jeffrey Ajer, the Executive Vice President and Chief Commercial Officer of Biomarin Pharmaceutical Inc (NASDAQ:BMRN), sold 5,000 shares of the company.
- Zacks
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IMVT, KYMR and LGND well amid volatility.
© 2024 Yahoo. All rights reserved.